[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620209":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":10,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":10,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy Controls",null,"CMR criteria:\n\nAnatomically intact cardiac structures: LVEF, ventricular volumes, and wall thickness within sex- and BSA-adjusted reference ranges (LVEF ≥55%, LVEDVi \\\u003C82 mL\u002Fm² for females, \\\u003C97 mL\u002Fm² for males); Absence of pathological tissue characteristics (negative LGE); Normal hemodynamic profile: Competent valvular function without hemodynamically significant regurgitation or stenosis.\n\nClinical exclusion criteria: No history of coronary artery disease, inflammatory cardiomyopathy, or electrophysiological abnormalities requiring intervention",[13],"Diagnostic Test: Magnetic Resonance Imaging with Contrast",{"label":15,"type":10,"description":16,"interventionNames":17},"Myocardial Diseases","Patients with various myocardial diseases including Fabry disease, Iron-overload, atrial fibrillation (AF), hypertension, aortic stenosis (AS), chronic myocardial infarction (MI), acute MI, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), arrhythmogenic cardiomyopathy (ACM), acute myocarditis, chronic myocarditis, cardiac amyloidosis, cardiac tumor, congenital heart disease, and suspected transplant rejection.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Magnetic Resonance Imaging with Contrast","Participants in this arm undergo a single, standardized cardiac MRI scan with gadolinium-based contrast agent.",[9,15],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Huaying Zhang, Doctor","CONTACT","86 13695310578","zhy_dreamer@163.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Fuwai Hospital, Chinese Academy of Medical Sciences","RECRUITING","Beijing","Beijing Municipality","100000","China",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Minjie Lu","Department Director","100620209",false,"NCT07354646","The Application of T1 Mapping in Real-World","The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort","Inclusion Criteria:\n\n1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.\n2. Specific disease categories include:\n\n   * Cardiomyopathies (HCM, DCM, RCM, ACM)\n   * Infiltrative disorders (cardiac amyloidosis, Fabry disease)\n   * Inflammatory conditions (acute\u002Fchronic myocarditis)\n   * Ischemic heart disease (acute\u002Fchronic MI)\n   * Valvular heart disease (aortic stenosis)\n   * Arrhythmic conditions (atrial fibrillation)\n   * Metabolic disorders (iron-overload)\n   * Neoplastic conditions (cardiac tumors)\n   * Congenital heart disease\n   * Post-transplant evaluation\n3. All diagnoses must be confirmed using established guideline-based criteria:\n\n   * Echocardiographic parameters meeting disease-specific cutoffs\n   * Cardiac MRI findings consistent with current consensus criteria\n   * Laboratory biomarkers supporting respective diagnoses\n   * Histopathological confirmation when clinically indicated\n\nExclusion Criteria:\n\n* Presence of multiple cardiomyopathy diseases or risk factors simultaneously\n* Contraindications to CMR examination\n* Poor image quality precluding accurate T1 mapping analysis\n* Incomplete clinical data for definitive diagnosis confirmation\n* Pregnancy or lactation\n* Inability to provide informed consent",true,"ALL",{"count":59,"type":60},2000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are:\n\nWhat are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler \"native T1\" measurement (without contrast dye) instead of the more complex \"ECV\" measurement (which requires contrast dye) for diagnosis?\n\nPatients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping",[64,65,66,67,68],"Myocardial Infarction (MI)","Hypertrophic Cardiomyopathy (HCM)","Dilated Cardiomyopathy (DCM)","Arrhythmogenic Cardiomyopathy","Myocarditis","2026-01-12",{"date":71,"type":72},"2026-01-21","ACTUAL",{"date":74,"type":72},"2020-03-01",{"date":76,"type":60},"2026-12-01",{"name":5,"class":6},1]